Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
... significantly greater A1C reduction, weight loss versus
weight gain and fewer episodes of hypoglycemia." ... was 4 percent with exenatide once weekly versus
19 percent with Lantus for patients on metformin ... and 20 percent with exenatide once weekly versus
44 percent with Lantus for patients on metformin ...
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
... also significantly reduced SLE disease activity versus
placebo based on a number of other measures, ... primary efficacy endpoint of superiority versus
placebo at Week 52.
A clinically and ... in both belimumab treatment
placebo, had their average prednisone dose
5-Year Study Published in Diabetologia Demonstrated Long-Term Safety of Lantus(R) Compared to NPH
... of Lantus(R) (insulin glargine [rDNA] injection) versus
NPH insulin on progression of retinopathy in ... controlled study with insulin glargine versus
NPH human insulin ," said lead investigator ... the retinal safety profile of Lantus(R) versus
NPH in 1024 patients (Lantus(R) once daily: 515 ...
New Study Shows that Prebiotics, as Used by Jackson GI Medical, Increases Lifespan by 33%
... prebiotics had an 80% survival rate to 24 months versus
a 50% survival rate for the control group rats ... reductions in cholesterol and body weight versus
the control group.
Significantly, the ... has repeatedly shown synergistic health benefits versus
the more common single-prebiotic fibers such as ...
Data Demonstrated ACTEMRA(R) (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients
... with methotrexate plus placebo (0.29, 0.34 versus
1.1, respectively; p<0.001). In addition, ... plus placebo-treated patients (81%, 85% versus
67%, p less than or equal to 0.0001), as measured ... a post-hoc analysis of the AMBITION ( A ctemra versus
M ethotrexate double- B lind I ...
Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
... to placebo (5 percent for tadalafil 40 mg, versus
16 percent with placebo)(4,5). Additionally, the ... mg were headache (42 percent for tadalafil 40 mg, versus
15 percent with placebo), myalgia (14 percent for tadalafil 40 mg, versus
4 percent with placebo) and flushing (13 percent ...
Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
... at 6, 12, 18 and 24 months for lorcaserin versus
placebo were 2.1% vs. 1.9% (p=0.88), 2.7% vs. ... evaluated 10 mg of lorcaserin dosed twice daily versus
placebo over a two-year treatment period in obese ... 10 mg of lorcaserin dosed once or twice daily versus
placebo over a one-year treatment period in obese ...
Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
... five years) previously demonstrated by Avandia versus
metformin and sulfonylurea in the ADOPT study.
... randomized to Avandia (61 events or 2.7 percent versus
29 events or 1.3 percent) (hazard ratio=2.10, 95 ... deaths from any cause (136 events or 6.1 percent versus
157 events or 7 percent for control) (hazard ...
Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry
... a single fixed dose of lurasidone 80 mg/day versus
placebo. Lurasidone 80 mg/day produced statistically significant improvement versus
placebo in both primary and secondary efficacy ... using the Barnes Akathisia Scale) for lurasidone versus
Lurasidone was well-tolerated ...
Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
... combination of vandetanib 100mg with docetaxel versus
docetaxel alone. The study enrolled 1391 patients ... study evaluating vandetanib 100mg plus pemetrexed versus
pemetrexed alone. The study enrolled 534 patients ... study evaluating the efficacy of vandetanib 300mg versus
erlotinib 150mg. The study enrolled 1240 patients ...
Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Those in Women
... the Recurrence Score(R) was 53.6 percent in males versus
53.4 percent in females, intermediate risk of recurrence was 35.2 percent in males versus
36.3 percent in females, and high risk of recurrence was 11.2 percent in males versus
10.3 percent in females.
Despite the ...
Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
... the median time to RECIST progression was 4.8, versus
2.8 for placebo.(11) BIBF 1120 is an oral ... Ingelheim Pharmaceuticals. "BIBW 2992 and BSC versus
Placebo and BSC in Non-Small Cell Lung Cancer ... of EGFR and HER2 plus best supportive care (BSC) versus
placebo plus BSC in patients with NSCLC failing ...
New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
... in the CYP2C19 gene that reduced its function versus
9.8 percent (N=1048) in patients without a ... attack, or stroke by 19 percent (9.9 percent versus
12.1 percent), with an increased risk of major ...
(3) Wiviott, S, Braunwald, E, et al. Prasugrel versus
Clopidogrel in Patients with Acute Coronary ...
Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
... in lung function from baseline of
6.6% (p=0.001 versus
placebo). Lung function improved at week 6 and ... treated with Bronchitol and dornase
alfa (p=0.008 versus
placebo) and those being treated with Bronchitol alone
Consistent loss of lung ...
New Studies on Once-Daily Extended Release Pramipexole Presented at American Academy of Neurology Annual Meeting
... and tolerability of pramipexole extended release versus
the currently available pramipexole immediate ... release and immediate release formulations versus
placebo after 18 weeks and 33 weeks of treatment, ... group, the mean change was -2.7 points at week 33 versus
-4.2 points at week 18, a worsening of +1.5 ...
SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease
... of percutaneous coronary intervention (PCI) versus
coronary artery bypass graft (CABG) surgery ... demonstrates that the cost effectiveness of PCI versus
CABG depends largely on patient characteristics, ... the increase in repeat revascularization for PCI versus
CABG was greatest -- CABG provided slightly more ...
Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
... Significantly Suppressed Bone Turnover Markers versus
Raloxifene in Postmenopausal Women with ... and nasopharyngitis in the arzoxifene group versus
the raloxifene group, whereas significantly fewer ...
About the " NEXT " Study
Raloxifene: 12-month Effects on Bone Mineral ...
Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C
... rates of serious and/or severe adverse events versus
peginterferon alfa-2a -
- Filing of global ... dose of albinterferon alfa-2b every two weeks, versus
the treatment group receiving the standard dose ... Phase 3 Clinical Trials of Albinterferon Alfa-2b versus
HGS has conducted two ...
Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
... treatment with the 25 mg dose and the 50 mg dose versus
placebo (p < 0.01 for all comparisons). ... of 5.7 SBMs during the first week of treatment versus
1.6 SBMs per week during the baseline period. The increase in SBMs versus
placebo was maintained over the 28-day treatment ...
New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer
... compared first-line XELOX (Xeloda + oxaliplatin) versus
FOLFOX-4 (intravenous bolus and infusional ... using a two by factorial design, XELOX + placebo versus
XELOX + Avastin (7.5 mg/kg q3w) versus
FOLFOX-4 + ...
Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
... compared with docetaxel
monotherapy (9.8 versus
7.0 months, respectively).
The safety ... cardiac events was 5% in the
combination group versus
4% in the monotherapy group (>/= Grade 2 ... - Neutropenia - 66% (Grade 3/4 57%) versus
65% (Grade 3/4 59%), with
Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
... with Femara as the optimal treatment strategy versus
EAST HANOVER, N.J., Dec. 11 ... a survival benefit for an aromatase inhibitor versus
tamoxifen in the monotherapy setting immediately ... early significant reduction in distant metastases versus
tamoxifen, at a median duration of follow-up of ...
New Keppra XR(TM) Data Highlight Its Role for Patients with Partial-Onset Seizures
... extended-release tablets comparing tolerability versus
levetiracetam immediate release (IR) and ... XR is associated with any tolerability advantages versus
the same daily dose of levetiracetam IR. ... once-daily had lower rates of some adverse events versus
levetiracetam IR twice-daily.
-- In ...
Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
... less clinically relevant bleeding (5.2 percent versus
7.3 percent) and less major bleeding (0.8 percent versus
3.8 percent) in those treated with ... of recurrent venous thromboembolism (2.3 percent versus
3.2 percent) and fatal or non-fatal pulmonary ...
Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting
... rates in the FCR arm (24 percent versus
13 percent, respectively). While median overall ... were similar in each treatment arm (50 percent versus
48 percent, respectively). Overall, the FCR ... darbepoetin alfa plus red blood cell transfusions versus
red blood cell transfusions alone for the ...
Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
... allopurinol for three days, with one day overlap) versus
allopurinol alone, which showed a reduction in ... uric acid levels for the sequential combination versus
allopurinol alone (p=0.06).
Tumor lysis ... plasma uric acid >7.5mg/dL was 90% with Elitek versus
53% with allopurinol and 77% with ...
Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders
... ed Study Comparing Rituximab and Dexamethasone versus
Dexamethasone Alone in ITP: Results of ... arm (2 percent in dexamethasone arm versus
6 percent in dexamethasone-plus-rituximab arm).
... compared with the traditional arm (28.7 percent versus
9.5 percent); however, no life-threatening or ...
Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
... Statistically significant reduction in pain versus
Bup/epi in patients receiving EXPAREL 450mg at ... in both EXPAREL 300mg and 450mg patient groups versus
active control, 6.4 vs. 7.8 pain intensity and ... in the EXPAREL 450mg group avoided all opioid use versus
zero percent (0%) of patients in the active ...
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
... Phase III, Randomized, Open-Label Study of 400 Mg versus
800 Mg of Imatinib Mesylate in Patients with ... International Randomized Study of Interferon versus
STI571 (IRIS) 7-Year Follow-up: Sustained ... the upper limit of normal at 2 consecutive visits versus
five (1.7%) patients treated with deferoxamine. ...
Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD
nights, and rescue medication use versus
-- Both doses of SYMBICORT were ... mcg only), and rescue medication use versus
-- Both doses of SYMBICORT were well-tolerated versus
placebo for up to 12 months.(4) ...
Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections
... test-of-cure visit was
82.2 percent for iclaprim versus
85.3 percent for linezolid in the
intent-to-treat ... were:
gastrointestinal disorders (7.4 percent versus
10.4 percent for iclaprim
and linezolid, ... and administration site
conditions (4.2 percent versus
3.9 percent); nervous system disorders ...
SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery
... group and the PCI
group (13.6 percent for CABG versus
15.8 percent for PCI, p=0.44), as well
as similar ... MI) for the two groups
(9.1 percent for CABG versus
7.0 percent for PCI, p=0.29). As expected, ... higher in the PCI group (12.0
percent for PCI versus
6.7 percent for CABG, p=0.02), while the rate ...
Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
... patients in the QID group had a clinical response versus
the placebo QID group (P < 0.0001); ... the Durezol BID patients had a
clinical response versus
42.5% of patients in the placebo BID group (P ... statistically significant
for the Durezol groups versus
the placebo groups in both the QID and ...
Data From Multiple Clinical Trials of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented at TCT 2008
... the clinical efficacy
and safety of Genous versus
a sirolimus-eluting stent and a bare metal
stent ... of Endothelial
Progenitor Cell Capture Stent versus
Polymer-Coated Stent versus
Bare Metal Stents in Patients Undergoing
Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
Status Scale (EDSS), with early versus
delayed treatment. This effect first
appeared at ... to patients with delayed treatment,
0.27) despite the latter receiving at least three ... 2008.
(2) Kappos L et al. Effect of early versus
delayed interferon beta-1b
treatment on ...
Interface Biologics' Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
significant reductions (88%) in thrombus versus
(Carbothane(TM)) control (data ... showed a significant reduction in thrombus versus
polyurethane control, and were not statistically different in
antithrombotic efficacy versus
a commercially available heparin ...
Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
... (bolus insulin) produced greater A1C
pre-mixed insulin in people with type 2 diabetes. ... compared to pre-mixed insulin (68 (47%) versus
43 (28%); p=0.0004).
LANTUS(R)/APIDRA(R) provided ... costs with
insulin glargine plus glulisine versus
pre-mix - a prospective,
observational study with ...
Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults With Asthma
... percentage of
patients receiving SYMBICORT versus
those receiving budesonide pMDI and
placebo ... begin to work (except for SYMBICORT versus
budesonide pMDI in
Study 1 [P=.073]).(1) The ... of SYMBICORT(R) (160/4.5 micrograms) versus
(budesonide and formoterol) in ...
Two New Alzheimer's Disease Studies Show Advances Against Different Treatment Targets
... a 34.2 percent
change from baseline (p=0.067, versus
placebo) was seen; by Week 16, a 62.4
percent improvement from baseline was observed (p=0.038, versus
showing a durable response four weeks ... an 11.2 percent change
from baseline (p=0.032, versus
placebo), and remained significant at Week
Results From the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) Study
... of aortic valve disease events alone (308 versus
326; HR 0.97; 95%
CI 0.83 to 1.14). The ... (15.7%) in the simvastatin plus ezetimibe group versus
(20.1%) in the placebo group.
The study ... than among those assigned placebo (93 [9.9%] versus
[7.0%]; unadjusted p=0.03), and there were ...